Diligence memo · auto-generated · as of July 2, 2026
Delpor, Inc.
Delpor, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Delpor, Inc. operates in Pharmaceuticals, based in SAN FRANCISCO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Delpor, Inc. has raised $1.4M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $900K on 2010-06-10.
Most recent recorded round closed around 2013-09-09.
Valuation (modeled)modeled
Provath models Delpor, Inc. at approximately $22M (range $263K–$252M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.96× the median modeled value of Pre-Seed Pharmaceuticals companies in 2013–2015 (87 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 39 months.
Last raise 12.8 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.9× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 23% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 29% of those peers.
Closest niche peers: IPM Safety Services, Inc., Scioderm, LLC, Chondrial Therapeutics, LLC, OnCore Biopharma, Inc., VR1 Corp.
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.